Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: Jim Wang who wrote (711)	1/15/1998 12:04:00 PM
From: Lucky	Read Replies (2) \| Respond to of 3578

Lu Classic example here of too many shorts.Must be at least 2mil short interest in a float of 5mil now.Average short price of 14 1/2.Everyone anxious to cover at 12 but telling everyone else to wait for 10.Too much demand at 12 now.Now every short is looking at each other wondering who is going to cover first. Tomorrow should be an up day as many GERN shorts cover due to weekend news and impatience.I doubt that this stock will fall to 11 in the next 4 weeks.Today will be the bottom for a while,maybe even a few weeks. Good Luck. Lucky.

To: Jim Wang who wrote (711)	1/15/1998 12:12:00 PM
From: Haolin Ni	Respond to of 3578

Any one brought GERN please read the press release of last year, which indicated GERN is co-operative with Boehringer Mannheim but get no money the moment since it has no profitable product yet. We can only talk about the potential when GERN could get funding or milestone payment. biz.yahoo.com ''A large body of research indicates that telomerase is potentially the most promising marker for clinical diagnosis, as well as for predicting patient outcome and monitoring the effects of cancer therapy,'' said Dr. Manfred Baier, president biochemicals of Boehringer Mannheim. ''We are pleased to be able to expand our relationship with Geron as we pursue this very important opportunity in cancer diagnostics.'' According to the agreement, Geron will receive funding and milestone payments, as well as royalties on sales of new research and clinical products. Boehringer Mannheim will be responsible for all preclinical and clinical development of products, and subject to Geron's current licenses, will receive exclusive marketing rights. In the United States, Geron retains co-promotion rights with Boehringer.